{"created":"2023-05-15T15:58:09.818630+00:00","id":27491,"links":{},"metadata":{"_buckets":{"deposit":"7cef5bd9-c664-4111-a9e5-6eba0f0f8e64"},"_deposit":{"created_by":3,"id":"27491","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"27491"},"status":"published"},"_oai":{"id":"oai:shinshu.repo.nii.ac.jp:00027491","sets":["2668"]},"author_link":["108312","108317","108318","108314","108313","108316","108315"],"item_20004_biblio_info_27":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2011-12-10","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageEnd":"418","bibliographicPageStart":"411","bibliographicVolumeNumber":"59","bibliographic_titles":[{"bibliographic_title":"信州医学雑誌"}]}]},"item_20004_creator_3":{"attribute_name":"作成者(その他言語)","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"KOBAYASHI, Takashi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KOIZUMI, Tomonobu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YASUO, Masanori"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"TSUSHIMA, Kenji"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YAMAMOTO, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KUBO, Keishi"}],"nameIdentifiers":[{}]}]},"item_20004_date_19":{"attribute_name":"日付","attribute_value_mlt":[{"subitem_date_issued_datetime":"2015-09-24","subitem_date_issued_type":"Created"}]},"item_20004_description_14":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"A phase II study was conducted to evaluate the feasibility and efficacy of biweekly administration of paclitaxel and gemcitabine in patients with non-small cell lung cancer (NSCLC) who had been treated previously with platinum-based chemotherapy. Paclitaxel (150 mg/m2) and gemcitabine (1,000 mg/m2) were administered biweekly for at least 4 cycles. Thirty-one patients with a median age of 64 years (39-75 years) were enrolled in this study(stage IIIB/IV :11/20,PS 0/1/2:13/16/2).Partial response was observed in 7 cases (23%), and stable disease was seen in 18 cases (58%).Median survival time was 8.8 months with a one-year survival rate of 41.9 %.Hematological toxicities were mild and neutropenia of grade 3 or above was observed in one patient (3%). Non-hematological toxicities were also mild, including neurotoxicity (3%). Biweekly paclitaxel and gemcitabine combination chemotherapy was effective and tolerated well as second-line therapy against NSCLC.","subitem_description_type":"Other"}]},"item_20004_description_20":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Article","subitem_description_type":"Other"}]},"item_20004_description_22":{"attribute_name":"その他の資源識別子","attribute_value_mlt":[{"subitem_description":"信州医学雑誌 59(6): 411-418(2011)","subitem_description_type":"Other"}]},"item_20004_full_name_16":{"attribute_name":"公開者(その他言語)","attribute_value_mlt":[{"nameIdentifiers":[{}],"names":[{"name":"信州医学会"}]}]},"item_20004_identifier_23":{"attribute_name":"資源識別子URI","attribute_value_mlt":[{"subitem_identifier_type":"HDL","subitem_identifier_uri":"http://hdl.handle.net/10091/13507"}]},"item_20004_source_id_25":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0037-3826","subitem_source_identifier_type":"ISSN"}]},"item_20004_source_id_26":{"attribute_name":"処理レコードID(総合目録DB)","attribute_value_mlt":[{"subitem_source_identifier":"AN00120815","subitem_source_identifier_type":"NCID"}]},"item_20004_version_type_51":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"url":{"url":"https://soar-ir.repo.nii.ac.jp/?action=repository_action_common_download&item_id=4145&item_no=1&attribute_id=65&file_no=1"}}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"second-line chemotherapy","subitem_subject_scheme":"Other"},{"subitem_subject":"platinum-resistant","subitem_subject_scheme":"Other"},{"subitem_subject":"non-small cell lung cancer","subitem_subject_scheme":"Other"},{"subitem_subject":"neurotoxicity","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Phase II Trial of Biweekly Paclitaxel and Gemcitabine as Second-Line Chemotherapy for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Phase II Trial of Biweekly Paclitaxel and Gemcitabine as Second-Line Chemotherapy for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy"}]},"item_type_id":"20004","owner":"3","path":["2668"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-09-01"},"publish_date":"2020-09-01","publish_status":"0","recid":"27491","relation_version_is_last":true,"title":["Phase II Trial of Biweekly Paclitaxel and Gemcitabine as Second-Line Chemotherapy for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy"],"weko_creator_id":"3","weko_shared_id":3},"updated":"2023-05-15T22:04:48.040293+00:00"}